Analysis on why the import of Brivaracetam is banned

Brivaracetam/Brivaracetam is a new oral anti-epileptic drug, mainly used for the adjuvant treatment of focal epilepsy in adults. Its function is to reduce abnormal neuron discharge by highly selectively binding to SV2A protein, thereby effectively reducing the frequency of epileptic seizures. Clinical experience shows that brivaracetam has the characteristics of rapid onset of action, good tolerance, and relatively mild side effects. Compared with some traditional anti-epileptic drugs, it can significantly improve the quality of life of patients. The common specification is 50 mg × 60 tablets, and the price per box is about more than 4,000 yuan (exchange rate fluctuations may affect the price). It is suitable for patients who are refractory to medication or have poor compliance.

In China, the original version of Brivaracetam has not yet been approved for marketing, so patients cannot purchase it directly through formal channels. The main reasons for the ban on import include that the drug registration and approval process has not been completed, the lack of domestic clinical data and the need for local verification of safety and efficacy. Domestic drug regulatory authorities usually require new drugs to provide sufficient clinical evidence and quality control information before introduction to ensure patient safety. In addition, intellectual property rights and market authorization issues are also factors limiting imports. There are no widespread generic drugs on the market yet. At this stage, the main channel that patients can choose is to obtain original drugs through legal pharmacies, but they need to ensure that the source is formal.

The Pharmacy Guide emphasizes that when considering purchasing drugs, patients should ensure that the drugs are registered products, have legal batch numbers and proof of origin, and should be used under the guidance of professional doctors. The doctor will develop a dosage plan based on the patient's specific condition, epilepsy type and medication history, and regularly monitor the efficacy and safety of the medication. Such standardized management can maximize the therapeutic benefits of brivaracetam while reducing potential risks. Overall, Brivaracetam has clear application value in anti-epileptic treatment, but it still needs to wait for relevant approvals in the domestic market. Patients should obtain drugs and guidance through safe, legal and professional channels.

Reference materials:https://www.briviact.com/